Relistor and Hepatic lesion - a phase IV clinical study of FDA data

Summary:

Hepatic lesion is reported as a side effect among people who take Relistor (methylnaltrexone bromide), especially for people who are female, 50-59 old, also take Ambien, and have Breast cancer.

The phase IV clinical study analyzes which people have Hepatic lesion when taking Relistor. It is created by eHealthMe based on reports of 1,647 people who have side effects when taking Relistor from the FDA, and is updated regularly.

What is Relistor?

Relistor has active ingredients of methylnaltrexone bromide. eHealthMe is studying from 1,659 Relistor users. Check the latest studies of Relistor.

What is Hepatic lesion?

Hepatic lesion is found to be associated with 673 drugs and 622 conditions by eHealthMe. Check the latest studies of Hepatic lesion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

1,647 people reported to have side effects when taking Relistor.
Among them, 12 people (0.73%) have Hepatic lesion.

Among these 12 people:

What is the gender of people who have Hepatic lesion when taking Relistor? *

female: 75 %
male: 25 %

What is the age of people who have Hepatic lesion when taking Relistor? *

What are other drugs people take besides Relistor? *

What are other side effects people have besides Hepatic lesion? *

Joint Pain: 12 people, 100.00%
Pleural Effusion (water on the lungs): 12 people, 100.00%
Weakness: 12 people, 100.00%
Anaemia (lack of blood): 12 people, 100.00%
Constipation: 12 people, 100.00%
Nosebleed (bleeding from nose): 11 people, 91.67%
Pain: 11 people, 91.67%
Confusional State: 11 people, 91.67%
Osteonecrosis Of Jaw (death of bone of jaw): 11 people, 91.67%
Chest Pain: 11 people, 91.67%

What are the existing conditions these people have? *

Breast Cancer: 8 people, 66.67%
Metastases To Bone (cancer spreads to bone): 3 people, 25.00%
Wound: 2 people, 16.67%
Gout (uric acid crystals building up in the body): 2 people, 16.67%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Relistor and have Hepatic lesion?

- Check whether Hepatic lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Relistor:

Relistor (1,659 reports)

Hepatic lesion treatments and more:

Hepatic lesion (5,726 reports)

Browse all side effects of Relistor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic lesion:

Hepatic lesion (673 drugs)

Browse all the conditions that are associated with Hepatic lesion:

Hepatic lesion (622 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methylnaltrexone bromide (the active ingredients of Relistor) and Relistor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.